ChemicalBook > Product Catalog >API >Antineoplastic agents >Natural sources of antineoplastic >Colchicine


Colchicine Suppliers list
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Products Intro: Product Name:Colchicine
Purity:98% Package:56862/KG
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Colchicine
Purity:99% Package:100g,500g,1kg,5kg,10kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: CAS:64-86-8
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Products Intro: Product Name:Colchicine
Company Name: PI & PI BIOTECH INC.
Tel: 020-81716320
Products Intro: Product Name:Colchicine
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Remarks:N-[(7S,12aM)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
Colchicine Chemical Properties
Melting point 150-160 °C (dec.)(lit.)
alpha -250 º (c=1, alcohol)
Boiling point 522.37°C (rough estimate)
density 1.2770 (rough estimate)
refractive index 1.5614 (estimate)
storage temp. Poison room
solubility H2O: 10 mg/mL
pka12.36(at 20℃)
form powder
color white to yellow with a green cast
Water Solubility 45 g/L (20 ºC)
Sensitive Light Sensitive
Merck 14,2471
BRN 2228813
Stability:Stable. Light sensitive. Incompatible with strong oxidizing agents.
CAS DataBase Reference64-86-8(CAS DataBase Reference)
NIST Chemistry ReferenceColchicine(64-86-8)
EPA Substance Registry SystemAcetamide, N-[(7S)-5,6,7,9-tetrahydro- 1,2,3,10-tetramethoxy-9-oxobenzo[ a]heptalen-7-yl]-(64-86-8)
Safety Information
Hazard Codes T+,T,Xi
Risk Statements 26/28-41-46
Safety Statements 13-45-36/37/39-28-26-53
RIDADR UN 1544 6.1/PG 1
WGK Germany 3
RTECS GH0700000
HazardClass 6.1
PackingGroup I
HS Code 29399990
Hazardous Substances Data64-86-8(Hazardous Substances Data)
ToxicityLD50 in rats (mg/kg): 1.6 i.v. (Rosenbloom, Ferguson); in mice (mg/kg): 4.13 i.v. (Beliles)
MSDS Information
Colchicine English
ACROS English
SigmaAldrich English
ALFA English
Colchicine Usage And Synthesis
AlkaloidsColchicine is a kind of alkaloid extracted from the crom or seed of the lily family plants, Colchicum autumnale, and is naturally presented in the Liliaceae Garland and Iphigenia with the contents being 0.11% and 0.1%. It is pale yellow needle crystals. It has slight odor and bitter taste with the melting point being 157 ℃. It is soluble in cold water, alcohol, chloroform and formaldehyde with poor solubility in hot water and is not easily soluble in benzene and ether. It is almost insoluble in petroleum ether with the pH of its 0.5% solution being 5.9. Hydrolysis with ammonia can reduce the toxicity. Colchicine is known to inhibit cell mitosis and has anti-tumor effect. In 1889, Italian scholar Pernice had first discovered the effect of colchicine on mitosis. He had described the metaphase of the lining cells in the stomach and intestines of dogs can be blocked colchicine with spindle being damaged and chromosome action paralyzed as well as a large number of abnormal mitotic cells existing in their metaphase. This abnormal division caused by the colchicine is known as colchicine mitosis (referred as the C mitosis). In the mutagenesis analysis of karyotyping and polyploid, colchicine is a most widely used chemicals. Its water concentration has a positive correlation with its action role. The higher the concentration is, the stronger the effect will be. Various kinds of plants and different organizations are known to have different response to colchicine. Generally, for young and rapidly divided organizations (e.g. germ of germinating seeds), the processing time can be shorter and the concentration should be lower; on the contrary, the processing time can be longer and the concentration should be higher. The effective concentration of colchicine treatment is 0.01 to 0.4% with the concentration of 0.2% having the mostly wide range. For example, if we drop 0.2 to 0.4% of colchicine solution on the diploid watermelon seedlings growing point once a day for four consecutive days, and keep the shade and humidity, you can induce tetraploid watermelon. For cereal crops such as rice, you can have robust seedling with four or more leaves cut an incision in the root neck with the degree within not cutting the growing point and immerse it into the 0.025 to 0.05% colchicine solution, submerge the incision, you can also obtain the tetraploid plants after 8 to 14 days (20 ℃). Currently, the colchicine is widely used for the chromosome doubling for haploid plants obtained from the culture of anther (powder), ovary culture.
Anti-gout drugColchicine has a good efficacy in treating acute gout and can quickly relieve pain and can prevent the onset of arthritis with its mechanism of action related to the inhibition of white blood cells and proliferation activities and the effect on lysosomal release.
The pharmacological effects of this product are through reducing activity and phagocytosis of leukocytes in the inflammatory tissue and reducing the inflammation caused by uric acid crystals, and thus playing effects of inflammation, swelling and pain effect, therefore it has selective anti-inflammatory effect on the acute gouty arthritis. In addition the product is also a kind of mitosis toxins with strong inhibitory effect of cell division, making the cells stopped in their division time and leading to tumor cell death, and therefore being used for cancer treatment. This product is easily absorbed after oral administration with 30% binding to plasma proteins and the plasma concentration reaching peak at 0.5 to 2 hours after oral administration. The plasma concentration peak after oral administration of 2mg is about 2.2ng/ml. It can play its efficacy at 12 hours after the administration in the case of acute gout and the efficacy can sustain 50 to 70 hours. The drug concentration in the isolated neutrophils is higher than the plasma concentrations and can maintain for as long as 10 days. This product is mostly metabolized by the liver with the metabolite and the prototype drug being excreted by the bile, further being reabsorbed through the intestinal tract with the unabsorbed part being discharged by the gut. The rest, about 10% to 20%, can be excreted through renal via urine.
This product does not affect the formation, dissolution and excretion of uric acid salt thereby has no effect on lowering the blood uric acid content. It is clinically used for the treatment of acute gouty arthritis attack, prevention of recurrent episodes of acute gouty arthritis, familial Mediterranean fever, leukemia, skin cancer, Hodgkin's disease, and aplastic anemia. It can also applied to the specific treatment of M cycle of various kinds of malignant diseases such as the breast cancer, lung cancer, esophageal cancer, cervical cancer, nasopharyngeal carcinoma, Hodgkin's disease, chronic myelogenous leukemia, and skin cancer.
The above information is edited by the chemicalbook of Dai Xiongfeng.
Side effectsThe adverse reaction has significant correlation with the dosage.
1. Gastrointestinal reactions: nausea, abdominal pain, diarrhea, vomiting and loss of appetite are common early side effects with the incidence being up to 80%. In severe cases, there may be dehydration and electrolyte imbalance. Upon such kind of performance, the drug should be immediately discontinued. Patients of long-term usage can get severe hemorrhagic gastroenteritis or malabsorption syndrome.
2. The blood system reactions: long-term medication can cause agranulocytosis, thrombocytopenia, aplastic anemia, and sometimes threaten the life.
3. Other toxic reactions; it is mainly manifested as urinary tract irritation symptoms such as urinary frequency, urgency, dysuria, hematuria, oliguria, or even renal failure. There may also be symptoms such as stomach, throat or skin burning sensation, and fever, bloody diarrhea, mental changes, myasthenia gravis, and respiratory depression.
4. During the period of taking colchicine, we should pay attention to check blood and liver and kidney function. Patients of hematopoietic dysfunction, liver and kidney damage, heart disease and severe gastrointestinal disease should administer with caution. Pregnant women should be disabled.
5. Muscles, peripheral neuropathy: proximal muscle weakness, and elevated serum creatine kinase; there may also be peripheral nerve axonal polyneuropathy at the same time of damaged muscle cells, manifested as numbness, tingling and weakness; muscle neuropathy is rare, often occurs for people of long-term use in the prevention of gout and those with mild renal insufficiency.
Dosage and administrationTablets: 0.5 mg per tablet; injection: 1mg, 2mg.
1. for the treatment of acute gout: for adult who orally administers tablets, apply the first dose of 0.5~1 mg, then take 0.5~0.6 mg every 1 to 2 hours until the joint symptoms or gastrointestinal symptoms get alleviated when you can discontinue the treatment. Usually a total dose of 4~10 mg can play obvious efficacy. Note that the patients should administer the drug as early as possible to get excellent efficacy during the acute phase of medication. If the patients take intravenous injection with the first dose being 1~2mg, slowly inject with 20 mL of saline with the time of being no less than five minutes. If necessary, apply intravenous injection every 6 to 12 hours for 0.5~1 mg until it works with the total dose of 4~5 mg/d. Intravenous injection can give a better efficacy than oral administration, and can also significantly reduce the gastrointestinal reactions.
2. for the prevention of acute gout: Adults should take 0.5~0.6 mg of tablet per time with 2 times daily or intravenous injection of 1~2mg/d. 3. For the diagnosis test of gout: If the acute joints symptom gets alleviated after treatment, this will help confirm the diagnosis.
Hazardous characteristicsColchicine itself has a small toxicity, but after absorption, it can be metabolized (oxidized) in vivo to become the oxydicolchicine of a strong toxicity. It has a strong irritation effect on the digestive tract and can inhibit the blood cells, causing neutropenia deficiency and aplastic anemia. It can also cause paralysis on the nerve center and smooth muscle, resulting in vasodilation, and respiratory center paralysis and death. The human lethal dose of colchicine is 6mg~7mg. Mouse oral-LD ​​was 66.6mg/kg; LD50-intraperitoneal injection of mice is 3.5mg/kg. LD50-subcutaneous injection of rat is 4mg/kg.
This product has been applied for treating acute gout for a long time. Later, it was found that it has a strong inhibitory effect on the cell division. Medically, it has been applied to the treatment of various cancers, such as breast cancer, cervical cancer, esophageal cancer, skin cancer, and chronic myelogenous leukemia. However, due to the high colchicine toxicity, in order to reduce the toxicity and improve the efficacy, people has modified the structure of colchicine with the toxicity of the resulting compounds being reduced, such as colchicine amine (TMCA, I), colchicine methylamine (Demecolcine II), it has now been used clinically.
Colchicine poisoning has a certain incubation period with symptoms often happening at 3d~6d after oral administration or injection. Symptoms include throat burning, nausea, vomiting, abdominal pain, diarrhea, watery stools, hematuria, urine retention, numbness, aching limbs, muscle cramps, hair loss, dilated pupils, and convulsion, paralysis of the central nervous system, and respiratory depression and death. In addition, it can also produce local reactions such as when the drug liquid is leaked out from the blood vessel upon injection, local tissue necrosis can occur. Poisoning is usually caused by ingestion or drug overdose. There are also individual cases in which people take it for suicide. The method of treatment is mainly symptomatic treatment. Patients of swallowing colchicine or patients of colchicine poisoning should be prohibited for the use of oxidants such as potassium permanganate to avoid generating a large number of colchicine oxide in the body which further increases the toxicity.
Chemical PropertiesIt is pale yellow crystal or crystalline powder with bitter taste and the color being changed upon exposure to light.. M.p. is 157 ℃ (recrystallized from ethyl acetate), specific rotation [α] 17D-429 ° (1.72%, water),-121° (0.9%, chloroform). It has the maximum absorption wavelengths being 243nm and 350.5 nm in ethanol. This product is easily soluble in water, ethanol and chloroform, soluble in benzene and ether, but insoluble in petroleum ether. The 0.5% solution of this product is acidic. LD50 (mouse, intraperitoneal) is 6.1mg/kg.
UsesIt can be used for the study of plant genetics; used as selenium reagent; clinically as anticancer drugs.
The product is a typical mitosis toxin. It can be used for treating acute gout and breast cancer. It can also be used as selenium reagent, for being applied to plant genetics and cancer research.
It is a kind of antineoplastic agents and anti-gout for being used for the treatment acute gout and for the treatment of tumors
Application in Acute Gouty Arthritis
  • Colchicine is an antimitotic drug that is highly effective in relieving acute gout attacks but has a low benefit-toxicity ratio. When colchicine is started within the first 24 hours of an acute attack, about two-thirds of patients respond within several hours. The likelihood of success decreases substantially if treatment is delayed longer than 48 hours after symptom onset.
  • Oral colchicine causes dose-dependent GI adverse effects (nausea, vomiting, and diarrhea) in 50% to 80% of patients before relief of the attack. Non-GI adverse effects include neutropenia and axonal neuromyopathy, which may be worsened in patients taking other myopathic drugs (e.g., statins) or in those with renal insufficiency. Colchicine should not be used concurrently with macrolide antibiotics (especially clarithromycin) because reduced biliary excretion may lead to increased plasma colchicine levels and agranulocytosis.
  • Colchicine should be reserved for patients with insufficient relief, intolerance, or contraindications to NSAIDs.
  • The usual oral colchicine dose is 1 mg initially, followed by 0.5 mg every 1 hour until the joint symptoms subside, the patient develops abdominal discomfort or diarrhea, or a total dose of 8 mg has been given.
  • IV colchicine should be avoided because it is associated with serious adverse effects (e.g., bone marrow suppression, tissue necrosis from local extravasation, disseminated intravascular coagulation, hepatocellular toxicity, and renal failure). If considered necessary, the recommended initial IV dose is 2 mg (if renal function is normal) diluted in 10 to 20 mL of normal saline administered slowly over 10 to 20 minutes in a secure, freeflowing IV line to avoid extravasation. This may be followed by two additional doses of 1 mg each at 6-hour intervals, with the total dose not exceeding 4 mg. After a full IV course, patients should not receive colchicine by any route for at least 7 days.
Production methodThis product is a kind of alkaloid extracted from the crom or seed of the lily family plants, Colchicum autumnale. The Colchicum autumnale powder was heated under reflux with 85% ethanol extraction for 4h, the resulted ethanol solution was concentrated under reduced pressure to a semi-gum, dilute with distilled water, with 10% sulfuric acid acidified filtrate with extraction by chloroform, and then concentrate the chloroform extract, the resulted crude colchicine obtained by crystallization was subject to re-crystallization to obtain the finished product. Calculated from the Colchicum autumnale powder, the total yield is 0.15%. In foreign countries, it is mostly extracted from the crom of the Liliaceae Colchicum genus Colchicum bulbs.
Take the bulbs and seeds of Iphigenia indica or Colchicum autumnale as raw material; obtain the final product with ethanol extraction and refining.
Categorytoxic substances
Toxicity gradingtoxic
Acute toxicityintravenous-rat LD50: 1.6 mg/kg; Oral-Mouse LD50: 5.886 mg/kg
Irritation dataeyes-rabbit 1%/3 days Severe
Chemical PropertiesYellow Solid
Chemical PropertiesColchicine is a pale yellow powder. It has little or no odor. It darkens on contact with light.
UsesBinds specifically with tubulin thus interfering with microtubule organization.
Usesantimitotic, antigout agent
UsesAn antimitotic agent that disrupts microtubles by binding to tubulin and preventing its polymerization. Stimulates the intrinsic GTPase activity of tubulin. Induces apoptosis in several normal and t umor cell lines and activates the JNK/SAPK signaling pathway.
Usesanti-inflammatory agent, mitosis inhibitor
UsesFor treatment and relief of pain in attacks of acute gouty arthritis.
UsesIn research in plant genetics (for doubling chromosomes).
DefinitionAn alkaloid plant hormone.
Flammability and hazard characteristicscombustible with fire causing decomposition into toxic nitrogen oxide fumes
Storage propertieswarehouse: cold, ventilated and dry; and food raw materials stored separately
Extinguishing mediaWater, carbon dioxide, dry, sandy soil
General DescriptionOdorless or nearly odorless pale yellow needles or powder that darkens on exposure to light. Used to treat gouty arthritis, pseudogout, sarcoidal arthritis and calcific tendinitis.
Air & Water ReactionsSlowly hydrolyzed in acidic solution, but unbuffered solutions are stable at 68°F for at least six months. Isomerizes on exposure to ultraviolet radiation.
Reactivity ProfileColchicine darkens on exposure to light. Incompatible with strong oxidizing agents. Also incompatible with mineral acids .
HazardAs little as 20 mg may be fatal if ingested.
Health HazardColchicine is classified as super toxic. Probable oral lethal dose in humans is less than 5 mg/kg, i.e. less than 7 drops for a 70 kg (150 lb.) person. Death results from respiratory arrest. The fatal dose varies considerably; as little as 7 mg of Colchicine has proved fatal.
Fire HazardStable.
Biological ActivityPlant-derived alkaloid that binds to tubulin and depolymerizes microtubules.
Safety Profileexperimentally by most routes. Human systemic effects: aplastic anemia, blood pressure depression, body temperature decrease, changes in kidney tubules, dyspnea, flaccid paralysis without anesthesia, gastrointestinal effects, kidney damage and hemorrhaging, muscle contraction or spasticity, muscle weakness, nausea or vomiting, respiratory stimulation, and somnolence. An experimental teratogen. Experimental reproductive effects. A severe eye irritant. Human mutation data reported. Inhibits the formation of microtubules and thus impairs cell division. When heated to decomposition it emits toxic fumes of NOx.
Potential ExposureColchicine is a drug used to treat gouty arthritis, pseudogout, sarcoidal arthritis; and calcific tendonitis.
First aidThis material is an alkaloid. If this chemical gets into the eyes, remove any contact lenses at once and irrigate immediately for at least 15 minutes, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts the skin, remove contaminated clothing and wash immediately with soap and water. Seek medical attention immediately. If this chemical has been inhaled, remove from exposure, begin rescue breathing (using universal precautions, including resuscitation 894 Colchicine mask) if breathing has stopped and CPR if heart action has stopped. Transfer promptly to a medical facility. When this chemical has been swallowed, get medical attention. Give large quantities of water and induce vomiting. Do not make an unconscious person vomit. Medical observation is recommended for 24 to 48 hours after breathing overexposure, as pulmonary edema may be delayed. As first aid for pulmonary edema, a doctor or authorized paramedic may consider administering a drug or other inhalation therapy
ShippingUN1544 Alkaloids, solid, n.o.s. or Alkaloid salts, solid, n.o.s. poisonous, Hazard Class: 6.1; Labels: 6.1- Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials
Purification MethodsCommercial material contains up to 4% desmethylcolchicine. Purify colchicine by chromatography on alumina and eluting with CHCl3 [Ashley & Harris J Chem Soc 677 1944]. Alternatively, an acetone solution on alkali-free alumina has been used, and eluting with acetone [Nicholls & Tarbell J Am Chem Soc 75 1104 1953]. It crystallises as yellow needles from EtOAc or CHCl3 with solvent of crystallisation which can be removed at ~70o. It is soluble in Et2O (0.5%), *C6H6 (1%) and H2O (4%). It is sold as “Colgout” for the treatment of gout and binds to tubulin. [Schreiber et al. Helv Chim Acta 44 540 1961, Scott et al. Tetrahedron 21 3605 1965, van Tamelen et al. Tetrahedron 14 8 1961, Beilstein 14 IV 946.]
IncompatibilitiesIncompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides, mineral acids. Keep away from light.
Colchicine Preparation Products And Raw materials
Raw materials
Tag:Colchicine(64-86-8) Related Product Information